Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Ovid Therapeutics Inc (OVID)

Ovid Therapeutics Inc (OVID)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 222,736
  • Shares Outstanding, K 70,710
  • Annual Sales, $ 390 K
  • Annual Income, $ -52,340 K
  • 60-Month Beta 0.71
  • Price/Sales 577.22
  • Price/Cash Flow N/A
  • Price/Book 2.54
Trade OVID with:

Options Overview Details

View History
  • Implied Volatility 189.36% ( -22.85%)
  • Historical Volatility 45.78%
  • IV Percentile 97%
  • IV Rank 57.91%
  • IV High 299.55% on 04/22/24
  • IV Low 37.73% on 11/02/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 11
  • Volume Avg (30-Day) 30
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 561
  • Open Int (30-Day) 541

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.22
  • Number of Estimates 4
  • High Estimate -0.17
  • Low Estimate -0.27
  • Prior Year -0.19
  • Growth Rate Est. (year over year) -15.79%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.99 unch
on 04/25/24
3.35 -10.75%
on 04/05/24
-0.10 (-3.24%)
since 03/25/24
3-Month
2.60 +15.00%
on 03/20/24
4.10 -27.07%
on 02/12/24
-0.61 (-16.94%)
since 01/25/24
52-Week
2.57 +16.34%
on 11/30/23
4.14 -27.76%
on 08/22/23
-0.08 (-2.61%)
since 04/25/23

Most Recent Stories

More News
Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates

Ovid Therapeutics (OVID) delivered earnings and revenue surprises of -5.56% and 10%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

OVID : 2.99 (-5.08%)
BLUE : 0.9125 (-1.13%)
Ovid Therapeutics (OVID) Upgraded to Buy: Here's What You Should Know

Ovid Therapeutics (OVID) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

OVID : 2.99 (-5.08%)
Ovid Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights

Anticipates filing an Investigational New Drug application for OV329, a potent GABA-aminotransferase inhibitor, and initiating a Phase 1 trial in the...

OVID : 2.99 (-5.08%)
Ovid Therapeutics Presents Preclinical Data on OV329 at the Epilepsy Foundation Pipeline Conference

OV329 demonstrated robust anti-seizure activity in multiple preclinical seizure and epilepsy models, including treatment-resistant seizuresData demonstrate...

OVID : 2.99 (-5.08%)
Ovid Therapeutics Reports First Quarter 2022 Financial Results and Corporate Highlights

Ovid anticipates filing an investigational new drug application (IND) for OV329, a potent GABA aminotransferase inhibitor, and initiating Phase 1 trials in...

OVID : 2.99 (-5.08%)
Ovid Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference

NEW YORK, April 08, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that...

OVID : 2.99 (-5.08%)
Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2021 Financial Results

Ovid executing on its strategy to build a leading epilepsy pipelineOV329 expected to enter the clinic in 2022Organization reshaped to reduce personnel by...

OVID : 2.99 (-5.08%)
Ovid Therapeutics to Participate at the Cowen 42nd Annual Health Care Conference

NEW YORK, March 04, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that...

OVID : 2.99 (-5.08%)
Healx and Ovid Therapeutics to Enter Strategic Partnership

– Ovid to License Gaboxadol to Healx – – Healx to Explore Gaboxadol in Combination Therapies for Fragile X, Other Indications – NEW YORK, N.Y. and...

OVID : 2.99 (-5.08%)
Ovid Therapeutics Expands Epilepsy Franchise with Novel KCC2 Activators

Exclusive license from AstraZeneca adds a unique candidate and a broad library of compounds to Ovid’s franchise of potential first-in-class anti-epileptic...

OVID : 2.99 (-5.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Ovid Therapeutics Inc. is a biopharmaceutical company. It engaged in developing therapies for patients with rare neurological disorders. The company's product pipeline consists of OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. It also involved...

See More

Key Turning Points

3rd Resistance Point 3.24
2nd Resistance Point 3.19
1st Resistance Point 3.09
Last Price 2.99
1st Support Level 2.94
2nd Support Level 2.89
3rd Support Level 2.79

See More

52-Week High 4.14
Fibonacci 61.8% 3.54
Fibonacci 50% 3.35
Fibonacci 38.2% 3.17
Last Price 2.99
52-Week Low 2.57

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar